Wednesday, 11 April 2012
The U.S. Contract Manufacturing Outsourcing Market Revives as Pharmaceutical Companies Increasingly Outsource After the Recession, Finds Frost & Sullivan
The upturn in the fortunes of pharmaceutical companies after the recession is mirrored by the U.S. contract manufacturing outsourcing (CMO) market, which is expected to grow at a compound annual growth rate (CAGR) of 8.3 percent from 2011 to 2016. The sterile segment accounts for the highest share of revenues, with 38.7 percent in 2011, which is expected to rise to 47.5 percent by 2016.
New analysis from Frost & Sullivan's (http://www.pharma.frost.com) Analysis of the United States Contract Manufacturing Outsourcing Market research finds that the market earned revenues of $10.73 billion in 2011 and estimates this to reach$15.97 billion in 2016.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, email@example.com, with your full name, company name, job title, telephone number, company email address, company Web site, city, state and country.
"The continued expansion of the U.S. pharmaceuticals industry and the big pharma's increased outsourcing to improve cost structure and focus on core competencies will significantly augment the market's revenue growth," said Frost & Sullivan Consultant Jesse Sullivan. "The pharmaceutical companies that had used their excess capacity during the downturn to retain in-house manufacturing are expected to gradually outsource as the economy improves."
Despite the inclination for pharmaceutical companies to outsource, R&D spending dipped from 2010 to 2011, resulting in fewer drugs being developed and marketed. As the CMO market's revenue inflow is contingent on drug development, the torpid R&D activity has slowed the pace of market development.